



Health
Management
International

1Q18 Results Presentation

13 November 2017

Disclaimer

This is a presentation of general information relating to the current activities of the Health Management International Ltd (“HMI”). It is given in summary form and does not purport to be complete. In addition, the presentation may contain forward-looking statements relating to financial trends for future periods, compared to the results for previous periods. Some of the statements contained herein are not historical facts but are statements of future expectations relating to the financial conditions, results of operations and businesses and related plans and objectives. The information is based on certain views and assumptions and would thus involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in these forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other companies, shifts in customer demands, customers and partners, changes in operating expenses, including employee wages, benefits and training, governmental and public policy changes, and the continued availability of financing in the amounts and the terms necessary to support future business. Such statements are not and should not be construed as a representation as to the future of HMI and should not be regarded as a forecast or projection of future performance. No reliance should therefore be placed on these forward-looking statements, which are based on the current view of the management of HMI on future events. The presentation is also not to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. HMI accepts no responsibility whatsoever with respect to the use of this document or any part thereof.

Key 1Q18 Highlights

Strong Financial Performance

	1Q18 YoY Growth
Revenue	6.9%
EBITDA	11.0%
Core NPAT ⁽¹⁾	1.4%
Core PATMI ⁽¹⁾	117.0%

Operational Update

- Total operational beds : 437 beds (↑1.2% YoY)
- Total patient load : 118.5K patients (↑5.4% YoY)
- Avg. inpatient bill size : MYR 7,644 (↑3.6% YoY)
- Avg. outpatient bill size : MYR 217 (↑12.2% YoY)

Key Updates

- Welcomes Heliconia Capital Management as strategic shareholder with SGD 11.0mn investment / 2.0% stake
- New HMI Performance Share Plan 2017 approved at the AGM
- On track to have paid down 50% of acquisition debt by December 2017

Outlook and Pipeline

- Mahkota Medical Centre (“**Mahkota**”): Increasing bed capacity from 266 beds to 300 beds in FY18 with eventual capacity of 340 beds
- Regency Specialist Hospital (“**Regency**”): Increasing bed capacity from 166 beds to 200 beds in FY18; to build an extension block to become a 380-bed tertiary hospital with capacity to expand to an eventual 500-bed hospital

Resilient Financial Performance

Group Income Statement

In MYR'000	1Q18	1Q17	%Δ
Revenue	117,054	109,460	6.9%
EBITDA	28,696	25,848	11.0%
<i>EBITDA margin (%)</i>	<i>24.5%</i>	<i>23.6%</i>	
Net profit after tax ("NPAT")	13,785	14,510	-5.0%
<i>NPAT margin (%)</i>	<i>11.8%</i>	<i>13.3%</i>	
Profit attributable to			
Equity holders ("PATMI")	13,786	6,170	123.4%
Non-controlling interests	(1)	8,340	
Adjustments for non-operational and one-off items			
Add: Forex loss/(gain) ¹	2,087	1,145	
Add: Professional fees ²	-	-	
Core NPAT	15,872	15,655	1.4%
<i>NPAT margin (%)</i>	<i>13.6%</i>	<i>14.3%</i>	
Core PATMI	15,873	7,315	117.0%
<i>PATMI margin (%)</i>	<i>13.6%</i>	<i>6.7%</i>	

Note:

(1) Forex loss/(gain) due to exchange differences arising from MYR denominated borrowings/receivables and cash in MYR denominated bank accounts at HMI's company level account

(2) The Group completed the consolidation of ownership of its two hospitals, the 48.9%-owned Mahkota and 60.8%-owned Regency to 100% each on 27 March 2017

Commentary

- 1Q18 revenue increased 6.9% YoY to MYR 117.1mn due to rising patient load and average bill sizes
- EBITDA increased 11.0% YoY to MYR 28.7mn, EBITDA margin expands to 24.5% due to higher revenue intensity and effective cost management
- 1Q18 Core PATMI grew 117.0% YoY to MYR15.9mn, after adjusting for non-operational foreign exchange losses. Shareholders continue to benefit following the completion of the consolidation⁽²⁾ as 100% of net income is attributable to shareholders

Strong Financial Position

Key Balance Sheet Items

In MYR'000	As at 30-Sep-17	As at 30-Jun-17
Cash and cash equivalents	78,308	76,754
Trade and other receivables	38,195	39,776
Inventories	13,786	13,551
Other current assets	5,622	8,375
Property, plant and equipment	285,375	278,551
Trade and other payables	68,482	67,746
Total Debt	144,638	163,748
Net Debt	66,330	86,994

Key Leverage Ratios


Total Debt / LTM EBITDA	1.5x	1.7x
Net Debt / LTM EBITDA	0.7x	0.9x
Net Debt / Equity ¹	0.3x	0.5x

Commentary


- Maintained strong balance sheet with cash position of MYR 78.3mn and net debt of MYR 66.3mn
- Total debt declines 11.7% from 30 June 2017 to MYR 144.6mn as at 30 September 2017 due to paydown of acquisition debt
- Net Debt / LTM EBITDA improves to 0.7x while gearing declines to 0.3x as at 30 September 2017

Consistent Patient Load Growth


Patient Load by Type ('000)



Patient Load by Nationality (%)



Bed Occupancy¹ and Operational Bed Count




Commentary


- 1Q18 patient load grew 5.4% YoY to 118.5k patients
- Increase in patient load primarily due to outpatients; inpatient admissions remained stable
- Growth in foreign patient load continues to outpace the growth in local patient load
- Total bed occupancy remained stable at 61% as operational beds increase to 437

High Revenue Intensity Per Patient


Average Inpatient Bill Size (MYR)



Average Outpatient Bill Size (MYR)



Total Hospital Revenue by Type (MYRm)



Commentary

- Total hospital revenue increased 6.3% YoY to MYR 112.3mn for 1Q18
- The YoY growth in average outpatient bill size at 12.2% outpaced the growth in average inpatient bill size at 3.6% to MYR 217 and MYR 7,644 respectively

Placement to Heliconia Capital Management

Details of the Placement

- Number of Placement Shares : 16,909,272 new shares
- Placement price : S\$0.65 per share
- Gross proceeds raised : S\$10.99 million
- Placement share percentage : 2.0% of the enlarged share capital
- Placement entity : Orchid 2 Investments Pte Ltd

Heliconia Capital Management

- Wholly-owned subsidiary of Singapore investment company Temasek
- Provides growth capital for Singapore's leading small and medium-sized enterprises, helping them become globally competitive companies

Rationale & Use of Proceeds

- A testament to HMI's experienced management team that has continuously achieved strong year-on-year growth at its hospitals
- Allows HMI access to Heliconia's network and resources to facilitate the Group's regional expansion
- In line with the Group's strategy to build relationships and synergistic partnerships that enhance shareholder value while charting sustainable growth at existing hospitals

Outlook and Pipeline

Updates on Mahkota

- Continued development of Mahkota Centres of Excellence
 - Introduction of new technologies at the In-Vitro Fertilisation (“IVF”) laboratory
 - New paediatric rehabilitation service catering to special needs children
 - New sub-specialities introduced including neonatology, rheumatology, trauma and spine surgery as well as periodontology
- Increasing bed capacity from 266 beds to 300 beds in FY18 with eventual capacity of 340 beds
- Airasia to commence direct flights to Guangzhou, Vietnam and Jakarta from Melaka airport

Updates on Regency

- Introduced Resident Medical Officers (“RMOs”) to bolster critical care capabilities round the clock
- Increasing bed capacity from 166 beds to 200 beds in FY18
- With the development of an extension block, Regency will become a 380-bed tertiary hospital with capacity to expand to an eventual 500-bed hospital
- Construction to commence in FY18 for estimated construction cost of MYR160mn, pending necessary approvals

Outlook and Prospects

- The Group continues to assess strategic collaborations and investment opportunities in Malaysia and the region
- Management will build on the Group’s success and growth over the past years by:
 - Focus on people development led by the Group’s newly appointed Chief People Officer
 - Enhancing service delivery
 - Continued recruitment of specialists and development of new clinical services
 - Managing cost pressures such as rising purchasing cost and staff cost
 - Further optimizing operating leverage
- Based on the current economic outlook and barring unforeseen circumstances, the Directors expect the Group to continue to grow in FY2018



Health
Management
International

APPENDICES

Income Statement – 1Q18 vs 1Q17

Income Statement

In MYR'000	1Q18	1Q17	%Δ
Revenue	117,054	109,460	6.9%
Cost of services	(76,426)	(71,632)	6.7%
Gross profit	40,628	37,828	7.4%
<i>Gross margin (%)</i>	<i>34.7%</i>	<i>34.6%</i>	
Interest income	272	419	-35.1%
Other gains/(losses), net	(1,054)	570	-284.9%
Distribution and marketing expenses	(1,111)	(682)	62.9%
Administrative costs	(17,145)	(17,844)	-3.9%
Finance costs	(2,072)	(518)	300.0%
Share of results of associates	-	477	-100.0%
Profit before tax	19,518	20,250	-3.6%
Income tax expense	(5,733)	(5,740)	-0.1%
Net profit after tax ("NPAT")	13,785	14,510	-5.0%
<i>NPAT margin (%)</i>	<i>11.8%</i>	<i>13.3%</i>	
Profit/(loss) attributable to			
Equity holders	13,786	6,170	123.4%
Non-controlling interests	(1)	8,340	-100.0%

Commentary

- **Revenue:** Increased 6.9% YoY to MYR 117.1mn driven by higher patient load, an increase in average bill sizes at both hospitals, and contribution from the education business
- **Other gains/(losses), net:** Other losses of RM1.1mn was recorded in 1Q18 compared to other gains of RM0.6mn in the prior year due to higher foreign exchange losses of RM2.1mn recorded in 1Q18 compared to RM1.1mn in 1Q17.
- **Distribution and marketing expenses:** Increased 62.9% yoy to RM1.1mn due to increased marketing efforts
- **Finance costs:** Increased by MYR1.6mn due to drawdown of SGD 53.0 mn from the term loan facility for the purposes of the acquisition of noncontrolling interests in Mahkota and Regency¹



Health
Management
International

THANK YOU

Investor and media relations

Mr. Chong Yap, Tok

Mr. James Bywater

ir@hmi.com.sg

Tel: (65) 6438 2990